Market News

Prothena Corporation Plc – Ordinary Shares (NASDAQ:PRTA)’s Trend Up, Especially After Decreased Shorts

Prothena Corporation plc (NASDAQ:PRTA) Logo

Investors sentiment decreased to 0.86 in 2018 Q2. Its down 0.03, from 0.89 in 2018Q1. It is negative, as 31 investors sold Prothena Corporation plc shares while 28 reduced holdings. 20 funds opened positions while 31 raised stakes. 29.12 million shares or 2.41% less from 29.85 million shares in 2018Q1 were reported.
Geode Capital Mngmt Limited Liability holds 442,854 shares or 0% of its portfolio. Employees Retirement System Of Texas invested in 113,000 shares. 20,549 were accumulated by Bancshares Of Montreal Can. 535,060 were accumulated by Dimensional Fund Limited Partnership. New York State Common Retirement Fund holds 0% or 41,600 shares. Huntington Bancorp accumulated 73 shares. Parametric Portfolio Assoc Lc holds 10,982 shares. Jane Street Limited Liability Com owns 0% invested in Prothena Corporation plc (NASDAQ:PRTA) for 10,417 shares. Group One Trading L P holds 0.01% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA) for 48,228 shares. Focused Wealth Mgmt Inc stated it has 0.05% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA). Pinnacle Assoc stated it has 275,019 shares. Fmr Limited invested in 5.57M shares. 8 are held by Architects. Rhumbline Advisers holds 39,697 shares or 0% of its portfolio. Senzar Asset Limited Co has invested 0.72% in Prothena Corporation plc (NASDAQ:PRTA).

The stock of Prothena Corporation Plc – Ordinary Shares (NASDAQ:PRTA) registered a decrease of 3.1% in short interest. PRTA’s total short interest was 6.07 million shares in October as published by FINRA. Its down 3.1% from 6.27 million shares, reported previously. With 274,500 shares average volume, it will take short sellers 22 days to cover their PRTA’s short positions. The short interest to Prothena Corporation Plc – Ordinary Shares’s float is 16.72%.

The stock increased 5.70% or $0.7 during the last trading session, reaching $12.98. About 764,094 shares traded or 75.07% up from the average. Prothena Corporation plc (NASDAQ:PRTA) has declined 77.78% since October 21, 2017 and is downtrending. It has underperformed by 93.40% the S&P500.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $517.08 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

Among 9 analysts covering Prothena Corp (NASDAQ:PRTA), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Prothena Corp had 11 analyst reports since April 23, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Monday, April 23 by Oppenheimer. The rating was maintained by Deutsche Bank with “Buy” on Tuesday, April 24. As per Monday, April 23, the company rating was downgraded by Jefferies. The rating was maintained by Nomura on Tuesday, April 24 with “Buy”. Evercore downgraded the shares of PRTA in report on Monday, April 23 to “In-Line” rating. Barclays Capital downgraded Prothena Corporation plc (NASDAQ:PRTA) rating on Monday, May 21. Barclays Capital has “Sell” rating and $1200 target. As per Tuesday, April 24, the company rating was downgraded by BTIG Research. The company was downgraded on Monday, April 23 by Barclays Capital. The firm has “Hold” rating by RBC Capital Markets given on Monday, April 23. The firm earned “Overweight” rating on Friday, June 15 by Cantor Fitzgerald.

Another recent and important Prothena Corporation plc (NASDAQ:PRTA) news was published by Nasdaq.com which published an article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within 1-800 FLOWERS.COM, Bojangles’, Prothena …” on October 16, 2018.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*